Nanotechnology Is Fastest Growing Segment Fueling Growth Of Global Ebola Vaccine Market
![]() |
Ebola Vaccine Market |
The global Ebola Vaccine Market is estimated to be valued at
US$ 5.83 Bn in 2023 and is expected to exhibit a CAGR of 32.% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market Overview:
The Ebola vaccine market comprises live and non-live attenuated vaccines that
offer improved immunogenicity and safety against the Ebola virus disease. These
vaccines provide long term immunity against different strains of the virus and
aid in preventing outbreaks.
Market key trends:
The use of nanotechnology based vaccine platforms is witnessing high growth in
the Ebola vaccine market. Nanoparticle based vaccines offer multiepitope
immunogenicity by mimicking viral structures and stimulating both humoral and
cellular immune responses. They can encapsulate antigens, target specific
immune cells and release antigens in a controlled manner. For instance,
GlaxoSmithKline's VSV-EBOV vaccine uses the vesicular stomatitis virus vector
engineered to produce an Ebola virus protein to trigger an immune response. The
vaccine demonstrated high efficacy levels during clinical trials.
Segment
Analysis
The global Ebola vaccine market is segmented based on product type, strain
type, and end user. By product type, the live-attenuated vaccine segment holds
the largest share due to advantages such as easy administration, fewer doses
required for immunization, and lifelong protection offered by the vaccine. By
strain type, Zaire Ebola virus segment dominates as it causes largest number of
cases and deaths during Ebola outbreaks. By end user, the hospitals and clinics
segment is the major shareholder due to higher patient footfall and
availability of vaccination facilities.
The global Ebola vaccine market size is expected to grow at a CAGR of 32% over the forecast period due to increasing prevalence of Ebola virus disease and development of novel vaccines.
By region, North America is expected to grow at the fastest pace owing to robust research activities for Ebola vaccines and availability of advanced healthcare facilities. Europe holds the second largest share due to presence of major players and government funding for innovation.
Key players operating in the Ebola vaccine market are Merck & Co.Inc,
GlaxoSmithKline plc, Mapp Biopharmaceutical, Nanoviricides Inc., Bavarian
Nordic, Chimerix, Biocomo, Geneone Life Sciences Inc, NewLink Genetics
Corporation, Novavax Inc, Johnson & Johnson Private Limited, Arbutus
Biopharma, Sarepta Therapeutics, Hemispherx Biopharma Inc, IMV Inc, Peptineo,
Biocryst Pharmaceuticals Inc. Merck & Co.Inc dominates the market due to
its ERVEBO vaccine approved for prevention of Ebola virus disease.
Get more insights on this topic: https://www.newswirestats.com/ebola-vaccine-market-industry-insights-trendsebola-vaccine-market-2023-2030/
Comments
Post a Comment